1. Home
  2. AKBA vs CAL Comparison

AKBA vs CAL Comparison

Compare AKBA & CAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Logo Caleres Inc.

CAL

Caleres Inc.

HOLD

Current Price

$10.97

Market Cap

400.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
CAL
Founded
2007
1878
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Shoe Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
380.4M
400.3M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
AKBA
CAL
Price
$1.42
$10.97
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$5.25
$15.00
AVG Volume (30 Days)
2.3M
697.0K
Earning Date
05-07-2026
03-19-2026
Dividend Yield
N/A
2.58%
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
$85,513,000.00
Revenue This Year
N/A
$6.10
Revenue Next Year
N/A
$1.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.46
52 Week Low
$1.14
$8.80
52 Week High
$4.08
$17.53

Technical Indicators

Market Signals
Indicator
AKBA
CAL
Relative Strength Index (RSI) 54.02 51.40
Support Level $1.30 $10.24
Resistance Level $1.55 $11.88
Average True Range (ATR) 0.06 0.67
MACD -0.00 0.13
Stochastic Oscillator 67.65 61.83

Price Performance

Historical Comparison
AKBA
CAL

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About CAL Caleres Inc.

Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.

Share on Social Networks: